

Possible Colchicine Poisoning : Case Study

Abstract

We have experienced a case of colchicine toxicity presenting with rapidly progressive gastrointestinal symptoms, hemodynamic instability, and multiple organ failure.

An 86-year-old Japanese man presented to our hospital with subarachnoid hemorrhage transferring from another hospital where he had been treated with colchicine 0.5 mg three times daily for an elevated uric acid level. During his admission, he had a nosocomial COVID-19 infection. Then, he developed loss of appetite, and significant diarrhea, which continued for two days. He then developed shock and hypoxia and was transferred to intensive care unit (ICU). The laboratory data revealed pancytopenia, acute kidney injury, lactic acidosis, marked coagulopathy, elevated troponin I, and C-reactive protein with poor cardiac function and hypotension refractory to vasopressors. Despite intensive care, he expired on 2nd day of ICU admission. Because his cardiac function was depressed from the beginning and was not respond to inotropic support, direct myocardial damage, rather than septic cardiomyopathy was suspected. We, therefore, emphasize that colchicine poisoning should be suspected in patients with access to the drug and the typical toxidrome.

Key words : septic cardiomyopathy, typical toxidrome, anti-inflammatory agent, colchicine

Introduction:

“The anti-inflammatory agent colchicine is used mainly for the treatment and prevention of gout and familial Mediterranean Fever (FMF)”¹⁾²⁾. Recently it has been a discussion if it can be a possible treatment medicine for COVID-19 patient^{3,4)}. It has a narrow therapeutic index and unintentional colchicine toxicity is uncommon, but often associated with a poor outcome. We have experienced a case with rapidly progressed gastrointestinal symptoms, hemodynamic instability, and multiple organ failure due to possible colchicine toxicity.

Case presentation

An 86-year-old gentleman presented for treatment of subarachnoidal hemorrhage (SAH) with referring from another hospital. In his past medical history, the patient was suffered from sick sinus syndrome, which was treated with pacemaker implantation, congestive heart failure. During hospitalized at our hospital, the patient had a high uric acid level with mild gout attack that was treated with colchicine 0.5 mg three times daily for 2 weeks without any uric acid lowering medicine. After successful treatment for his SAH, the patient was diagnosed with COVID-19 infection due to close contact without any symptoms. Because of his high risk for COVID-19 infection, he was treated with Remdesivir and corticosteroid, and then he started to have significant diarrhea with a loss of appetite with mildly impaired renal function (Creatinine 1.21 mg/dl), mildly increased C-reactive protein (CRP 2.77 mg/dl) and thrombocytopenia (73,000 / μ L). These symptoms were continued for the next 2 days, although drip infusion was applied. Then the patient suddenly had shock status (ABP 75/40 mmHg) with desaturation (SAT 87 %) and was transferred into the ICU. The laboratory data

showed significant coagulopathy (Prothrombin time international normalized ratio >1.51), acute kidney injury (estimated glomerular filtration ratio; eGFR 19.6, serum creatinine 2.68 mg/dL), lactic acidosis (24.3 mmol/L) as well as pancytopenia. Troponin I was highly elevated (148 pg/mL) and CRP was elevated (20.78 mg/dL). Electrocardiography showed normal sinus rhythm with some pacing waves and premature ventricular contractions without ST-T changes. Given his symptoms and preliminary diagnostic findings, septic shock was suspected. The patient was fluid resuscitated, started on broad-spectrum antibiotics, and administered norepinephrine and vasopressin therapy. Over 24 hours, the patient remained in severe hypotension with peripheral circulatory failure with very high lactate (25.4 mmol/L) and severe multisystem organ failure developed. He was intubated, paralyzed, and treated with intravascular volume repletion, escalating doses of intravenous vasopressors (dobutamine, norepinephrine, vasopressin), broad-spectrum antibiotics, stress-dose steroids for refractory shock without improvement. The patient presented refractory hypoglycemia and low bicarbonate, which were treated with multiple-dose of bolus glucose and bicarbonate.

On the 2nd day of ICU accommodation, blood tests showed significantly elevated transaminase (AST 1576 U/L, ALT 504 U/L), ALP (504 U/L), BUN (78.2 mg/dL), creatinine (3.17 mg/dL) suggesting further deterioration of acute kidney injury and a liver damage. FloTrac sensor was applied to monitor cardiac output, and the initial reading was low cardiac index (1.5 L/min/m²). Within the next few hours, his hemodynamics were severely debilitated with wider QRS, reflecting progressive myocardial injury. A transthoracic echocardiogram revealed severe biventricular failure (left ventricular ejection fraction [LVEF]<10 %). On

admission, an echocardiogram revealed relatively good biventricular function (EF 65 %) with mild anteroseptal hypokinesis, moderate mitral regurgitation with backward pulmonary hypertension (estimated pulmonary arterial pressure; ePAP>70 mmHg), severe tricuspid regurgitation. At that time, colchicine toxicity was highly suspected. He was started on continuous renal replacement therapy (CRRT) for anuric renal failure. Packed red blood cell (PRBC) transfusion with platelet-rich plasma (PRP) was administered. Despite our management, his condition was debilitated without recovery. He was expired on the second day of ICU admission.

DISCUSSION

This patient presented us with severe progressive hypotension, pancytopenia, GI symptoms and high CRP. It was suspected septic shock initially, however high troponine I, leukocytopenia and anemia does not occur in initial phase of septic shock and most septic cardiomyopathy would be reversible. Gastrointestinal symptoms are also not popular in septic shock. These negative evidence may suggest possible colchicine toxicity, since colchicine poisoning is mostly diagnosed based on comprehensive clinical findings.

“Colchicine has been used for the treatment of acute pericarditis, gout, and familial Mediterranean fever”⁵). “In therapeutic doses, colchicine has pleiotropic properties, with nausea and vomiting as the most commonly noted side effects. Colchicine does not have a uric acid lowering action, but has an anti-inflammatory effect. Colchicine also has a narrow therapeutic index with a high mortality rate in supratherapeutic doses. The usual adult oral doses for acute gout is 1.2 mg/day and for gout prophylaxis is 0.5-0.6 mg/day three to four

times a week. High fatality rate was reported after acute ingestions exceeding 0.5 mg/kg. The lowest reported lethal doses of oral colchicine are 7-26 mg⁶⁾.

“Colchicine irreversibly binds to unpolymerized tubulin, which is incorporated into microtubules, affecting cellular processes that require cytoskeletal change”⁷⁾. “This includes neutrophil motility, vesical transportation, and cell mitosis”⁸⁾. “Gastrointestinal symptoms might cause dehydration and/or pre-renal azotemia, which caused increased level of colchicine. The pathophysiological mechanisms of colchicine’s therapeutic and toxic effects on cardiomyocytes are not well described. It is known that at low levels colchicine inhibits microtubule formation (polymerization), but at high levels, the drug promotes microtubule depolymerization”⁷⁾. “Microtubules are essential to cardiomyocyte function and are pivotal in mechanosignaling, contractility, and myocyte stiffness. Other studies report the effect of colchicine on excitation-contraction coupling and calcium fluxes⁹⁾ and endothelial function”¹⁰⁾

“Colchicine toxicity is difficult to treat, with no universally agreed-on antidote. It has been reported that troponin I is a reliable parameter for prediction of cardiovascular collapse in acute colchicine overdose¹¹⁾. Previous study¹²⁾ among 3302 patients, 43 (1.30 %) were inappropriately prescribed colchicine. Of these 43 patients, 11 had baseline renal and/or liver impairment”. Our patient had mildly impaired renal function (Cr. 1.05-1.33 mg/dL) on admission.

CONCLUSION

Based on our findings we emphasize that colchicine poisoning should be suspected in patients with access to the drug and the typical toxidrome (gastroenteritis, hypotension, lactic acidosis, and prerenal azotemia), particularly in patient with renal impairment. It is

imperative to recognize its features as it is associated with a high mortality rate when missed.

Consent

As per international standard or university standard, patient(s) written consent has been collected and preserved by the author(s).

Ethical Approval:

As per international standard or university standard written ethical approval has been collected and preserved by the author(s).

References:

1) Slobodnick A, Shah B, Pillinger MH, Krasnokutsky S. Colchicine: old and new. *Am. J. Med.* 2015;128: 461–70.

2) Alessandro Andreis, Massimo Imazio, Matteo Casula, Stefano Avondo, Gaetano Maria De Ferrari. Colchicine efficacy and safety for the treatment of cardiovascular diseases. *Intern Emerg Med.* 2021; 16(6): 1691–1700

3)Medine Cumhuri Cure, Adem Kucuk, Erkan Cure. Colchicine may not be effective in COVID-19 infection; it may even be harmful? *Clinical Rheumatology* 2020; 39:2101–2102.

4) Rafael Parra-Medina, Juan Camilo Sarmiento-Monroy, Adriana Rojas-Villarraga, Garavito, Giovanni Montealegre-Gómez, Arley Gómez-López. Colchicine as a possible therapeutic option in COVID-19 infection *Clin Rheumatol.* 2020; 39(8): 2485–2486

5) Finkelstein Y, Aks SE, Hutson JR, Juurlink DN, Nguyen P, Dobnov-Raz G et al.

Colchicine poisoning: dark side of an ancient drug. *Clin Toxicol (Phila)* 2010; 48: 407-14

6) Georges El Hasbani, Ali Jawad, Imad Uthman. Update on the management of colchicine resistant Familial Mediterranean Fever (FMF) *Orphanet J Rare Dis.* 2019; 14: 224

7) Angelidis C, Kotsialou Z, Kossyvakis C, Vrettou A-R, Zacharoulis A, Kolokathis F, et al.

Colchicine Pharmacokinetics and Mechanism of Action. *Curr Pharm Des.* 2018;24(6):
659-663.

8) Massimo Imazio, Mark Nidorf. Colchicine and the heart. *Eur Heart J.* 2021; 42(28):
2745–60

9) Robinson P, Prosser BL. Microtubule mechanics in the working myocyte. *J Physiol* 2017;
595: 3931-7.

10) Leung YY, Yao Hui LL, Kraus VB. Colchicine--Update on mechanisms of action and
therapeutic uses. *Semin Arthritis Rheum* 2015 Dec;45(3):341-50.

11) van Heyningen C, Watson ID. Troponin for prediction of cardiovascular collapse in acute
colchicine overdose. *Emerg Med J* 2005; 22:599-600.

12) Imai, S, Momo K, Kashiwagi H, Miyai T, Sugawara M, and Takekuma Y. Prescription of
Colchicine with Other Dangerous Concomitant Medications: A Nation-Wide Surgery Using
the Japanese Claims Database. *Biol Pharm. Bull* 2020; 43: 1519-25.